Icon

Jentadueto XR - (2.5 mg/1000 mg, 5 mg/1000 mg; Tablet ER)

Linagliptin and Metformin Hydrochloride Boehringer Ingelheim
2.5 mg/1000 mg, 5 mg/1000 mg; Tablet ER
Less Than $1000 mn
None None
More Than 5
Less Than 5
None None
Jentadueto XR (linagliptin and metformin hydrochloride extended-release) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate.
Yes
* **** ** ***** ** ******* *******, *** *** ******* ** *** ******* *** *******. ********* ** *** ******, ********** ** ** ********* ** * ******** ****** (****) ** ***. **, **** ** *** ******** *** ****** *** ******* ****** ****. ** ******* *** **** ********* ** ***.
Jentadueto XR Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11
*** **** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** *********
*** ****** *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** ********* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
*** **** *** \ ** -**- *** ********* ********* ******** ***** *** **** (******** ******)
*** ****** ** \ ** -**- *** ********* ********* ******** ***** *** **** (******** ******)
  1. *** **, **** : * ****-** ** ***** *** ***** ** *** *** *******.
  2. *** *, **** : *** **** ******** ********* ******** *** *** *** *********.
  3. *** **, **** : *** ****** ******** ********* ******** *** *** *** *********.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.